The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Some medtech stocks did decline in 2018, but many more increased in value.
Having won the most acquisitive crown in 2016, Stryker seems to be seeking the prize this year too, buying Invuity and spinal company K2M.
Big cap medtech is hiring, largely thanks to organic growth.
Big cap medtech disappoints – but still beats pharma.
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.